Abstract
The paper shows that bisphosphonates are now an integral part in the complex treatment of bone metastases. Their use reduces a risk for development of fractures, including those with spinal cord compression and hypercalcemia. The additional property of bisphosphonates is their ability to prevent bone mineral density loss during hormonal therapy with tamoxifen and aromatase inhibitors. There has been more and more information on the antitumor activity of bisphosphonates, as demonstrated by the ABCSG-12 study of zoledronate used in 1800 patients with early breast cancer. This property of bisphosphonate is also confirmed by the AZURE study in which addition of bisphosphonates to the standard neoadjuvant chemotherapy could increase the frequency of beneficial effects. Addition of bisphosphonates to chemotherapy or hormonal therapy improves the results of treatment and quality of life in cancer patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
